Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Peter H. Schafer"'
Autor:
Oday Salman, Lei Zhao, Jordana B. Cohen, Marie Joe Dib, Joe David Azzo, Sushrima Gan, A. Mark Richards, Bianca Pourmussa, Rob Doughty, Ali Javaheri, Douglas L. Mann, Ernst Rietzschel, Manyun Zhao, Zhaoqing Wang, Christina Ebert, Vanessa van Empel, Karl Kammerhoff, Joseph Maranville, Joseph Gogain, Jaclyn Dennis, Peter H. Schafer, Dietmar Seiffert, David A. Gordon, Francisco Ramirez‐Valle, Thomas P. Cappola, Julio A. Chirinos
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 17 (2024)
Background Kidney disease is common in heart failure with preserved ejection fraction (HFpEF). However, the biologic correlates and prognostic significance of kidney injury (KI), in HFpEF, beyond the estimated glomerular filtration rate (eGFR), are u
Externí odkaz:
https://doaj.org/article/005acfdc8a4844deafa49b506123ac19
Autor:
Oday Salman, Payman Zamani, Lei Zhao, Marie Joe Dib, Sushrima Gan, Joe David Azzo, Bianca Pourmussa, Arthur Mark Richards, Ali Javaheri, Douglas L. Mann, Ernst Rietzschel, Manyun Zhao, Zhaoqing Wang, Christina Ebert, Laura Liu, Kushan L. Gunawardhana, Danielle Greenawalt, Leon Carayannopoulos, Ching‐Pin Chang, Vanessa van Empel, Joseph Gogain, Peter H. Schafer, David A. Gordon, Francisco Ramirez‐Valle, Thomas P. Cappola, Julio A. Chirinos
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 17 (2024)
Background The role of cellular senescence in human heart failure (HF) remains unclear. The senescence‐associated secretory phenotype (SASP) is composed of proteins released by senescent cells. We assessed the prognostic significance and biologic p
Externí odkaz:
https://doaj.org/article/9ce69a1294c446d9a935a66c5df06d36
Autor:
Corinne Carland, Lei Zhao, Oday Salman, Jordana B. Cohen, Payman Zamani, Qing Xiao, Ashok Dongre, Zhaoqing Wang, Christina Ebert, Danielle Greenawalt, Vanessa van Empel, A. Mark Richards, Robert N. Doughty, Ernst Rietzschel, Ali Javaheri, Yixin Wang, Peter H. Schafer, Sarah Hersey, Leonidas N. Carayannopoulos, Dietmar Seiffert, Ching‐Pin Chang, David A. Gordon, Francisco Ramirez‐Valle, Douglas L. Mann, Thomas P. Cappola, Julio A. Chirinos
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 9 (2024)
Background Although several studies have addressed plasma proteomics in heart failure with preserved ejection fraction, limited data are available on the prognostic value of urinary proteomics. The objective of our study was to identify urinary prote
Externí odkaz:
https://doaj.org/article/31d03371ea994940952d131d3a850e78
Autor:
Peter H. Schafer, Alan J. Kivitz, Jianglin Ma, Shimon Korish, Donna Sutherland, Li Li, Ada Azaryan, Jolanta Kosek, Mary Adams, Lori Capone, Eun Mi Hur, Douglas R. Hough, Garth E. Ringheim
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 1, Pp 101-119 (2019)
Abstract Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mec
Externí odkaz:
https://doaj.org/article/39d20490cb6e49508dbe1a45ca6893e9
Autor:
Peter H. Schafer, Mary Adams, Gerald Horan, Francesca Truzzi, Alessandra Marconi, Carlo Pincelli
Publikováno v:
Drugs in R&D, Vol 19, Iss 4, Pp 329-338 (2019)
Abstract Background Apremilast, an oral phosphodiesterase (PDE) 4 inhibitor, has demonstrated efficacy in psoriasis, while its efficacy in atopic dermatitis (AD) was found to be modest. AD is a chronic inflammatory skin disease associated with activa
Externí odkaz:
https://doaj.org/article/6311f234a8234e55843aa86a3e9e665f
Autor:
Weiqian Chen, Julie Wang, Zhenjian Xu, Feng Huang, Wenbin Qian, Jilin Ma, Hwa bok Wee, Gregory S. Lewis, Rayford R. June, Peter H. Schafer, Jin Lin, Song Guo Zheng
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Apremilast is a novel phosphodiesterase 4 (PDE4) inhibitor suppressing immune and inflammatory responses. We assessed the anti-inflammatory effects of Apremilast in type II collagen (CII)-induced arthritis (CIA) mouse model. To determine whether Apre
Externí odkaz:
https://doaj.org/article/40cf4d87d17247b2ae2579960406c16d
Publikováno v:
Journal of Immunology Research, Vol 2015 (2015)
Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program.
Externí odkaz:
https://doaj.org/article/48a9a073ea914ccc9b94d9086f6650b5
Autor:
Dominique Verhelle, Kyle W.H. Chan, Peter J. Worland, George W. Muller, Peter H. Schafer, Anita K. Gandhi, Helen A. Brady, Kristen Jensen-Pergakes, I-Lin Lin, Laure Escoubet-Lozach
PDF file - 25K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46065e281e92f65bfabc7f3a092ba49e
https://doi.org/10.1158/0008-5472.22377467.v1
https://doi.org/10.1158/0008-5472.22377467.v1
Autor:
Dominique Verhelle, Kyle W.H. Chan, Peter J. Worland, George W. Muller, Peter H. Schafer, Anita K. Gandhi, Helen A. Brady, Kristen Jensen-Pergakes, I-Lin Lin, Laure Escoubet-Lozach
PDF file - 1247K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bda6d6563162511017ad15021b20b0
https://doi.org/10.1158/0008-5472.22377470.v1
https://doi.org/10.1158/0008-5472.22377470.v1
Autor:
Julio A. Chirinos, Lei Zhao, Alexander L. Reese-Petersen, Jordana B. Cohen, Federica Genovese, A. Mark Richards, Robert N. Doughty, Javier Díez, Arantxa González, Ramón Querejeta, Payman Zamani, Julio Nuñez, Zhaoqing Wang, Christina Ebert, Karl Kammerhoff, Joseph Maranville, Michael Basso, Chenao Qian, Daniel G.K. Rasmussen, Peter H. Schafer, Dietmar Seiffert, Morten A. Karsdal, David A. Gordon, Francisco Ramirez-Valle, Thomas P. Cappola
Publikováno v:
NEJM Evidence. 1